Category Archives: Immunology

Wuhan lab says there’s no way coronavirus originated there. Here’s the science. – Livescience.com

An unprecedented amount of research has been focused solely on understanding the novel coronavirus that has taken nearly 150,000 lives across the globe. And while scientists have gotten to know some of the most intimate details of the virus called SARS-CoV-2, one question has evaded any definitive answers Where did the virus come from?

Live Science contacted several experts, and the reality, they said, is that we may never know where this deadly coronavirus originated. Among the theories circulating: That SARS-CoV-2 arose naturally, after passing from bats to a secondary animal and then to humans; that it was deliberately engineered and then accidentally released by humans; or that researchers were studying a naturally-occurring virus that subsequently escaped from a high-security biolab, the Wuhan Institute of Virology (WIV) in China. The head of the lab at WIV, for her part, has emphatically denied any link to the institute.

Just today (April 18), the vice director of WIV Zhiming Yuan CGTN, the Chinese state broadcaster, said "there is no way this virus came from us," NBC News reported. "We have a strict regulatory regime and code of conduct of research, so we are confident."

Furthermore, the notion that SARS-CoV-2 was genetically engineered is pure conspiracy, experts told Live Science, but it's still impossible to rule out the notion that Chinese scientists were studying a naturally-occurring coronavirus that subsequently "escaped" from the lab. To prove any of these theories takes transparent data and information, which is reportedly not happening in China, scientists say. Several experts have said to Live Science and other media outlets have reported that the likeliest scenario is that SARS-CoV-2 is naturally occurring.

Related: 13 coronavirus myths busted by science

"Based on no data, but simply [a] likely scenario is that the virus went from bats to some mammalian species, currently unknown despite speculation, [and] spilled over to humans," said Gerald Keusch, associate director of the Boston University National Emerging Infectious Diseases Laboratories. This spillover event may have happened before the virus found its way into a live animal market, "which then acted as an amplifying setting with many more infections that subsequently spread and the rest is history," Keusch said. "The timeline is fuzzy and I don't think we have real data to say when these things began, in large part because the data are being held back from inspection," Keusch told Live Science.

The SARS-CoV-2 virus is most closely related to coronaviruses found in certain populations of horseshoe bats that live about 1,000 miles (1,600 kilometers) away in Yunnan province, China. The first known outbreak of SARS-CoV-2 in humans occurred in Wuhan and initially was traced to a wet seafood market (which sold live fish and other animals), though some of the earliest cases have no link to that market, according to research published Feb. 15 in the journal The Lancet.

Related: 11 (sometimes) deadly diseases that hopped across species

What's more, despite several proposed candidates, from snakes to pangolins to dogs, researchers have failed to find a clear "intermediate host" an animal that would have served as a springboard for SARS-CoV-2 to jump from bats to humans. And if horseshoe bats were the primary host, how did the bat virus hop from its natural reservoir in a subtropical region to the bustling city of Wuhan hundreds of miles away?

These questions have led some people to look elsewhere in the hunt for the virus's origin, and some have focused on the Wuhan Institute of Virology (WIV).

In 2015, WIV became China's first lab to reach the highest level of bioresearch safety, or BSL-4, meaning the lab could host research on the world's most dangerous pathogens, such as Ebola and Marburg viruses. (SARS-CoV-2 would require a BSL-3 or higher, according to the Centers for Disease Control and Prevention.) Labs like these must follow strict safety guidelines that include filtering air, treating water and waste before they exit, and requiring lab personnel to shower and change their clothes before and after entering the facility, Nature News reported in 2017.

These types of labs do spur concerns among some scientists who worry about the risks involved and the potential impact on public health if anything were to go wrong, Nature News reported.

Related: The 12 deadliest viruses on Earth

WIV was not immune to those concerns. In 2018, after scientist diplomats from the U.S. embassy in Beijing visited the WIV, they were so concerned by the lack of safety and management at the lab that the diplomats sent two official warnings back to the U.S. One of the official cables, obtained by The Washington Post, suggested that the lab's work on bat coronaviruses with the potential for human transmission could risk causing a new SARS-like pandemic, Post columnist Josh Rogin wrote.

"During interactions with scientists at the WIV laboratory, they noted the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory," the officials said in their cable dated to Jan. 19, 2018.

When reports of the coronavirus first popped up in China, the U.S. Deputy National Security Advisor Matthew Pottinger reportedly suspected a potential link to China labs. In mid-January, according to a New York Times report, Pottinger asked intelligence agencies like the C.I.A., particularly individuals with expertise on Asia and weapons of mass destruction, to investigate this idea. They came up empty-handed, the Times reported.

Meanwhile, the lab at the center of these speculations had long been sounding the alarm about the risk of the SARS-like coronaviruses they studied to spawn a pandemic.

The head of the lab's bat-coronavirus research, Shi Zhengli, published research on Nov. 30, 2017 in the journal PLOS Pathogens that traced the SARS coronavirus pandemic in 2003 to a single population of horseshoe bats in a remote cave in Yunnan province. The researchers also noted that other SARS-like coronaviruses discovered in that cave used the ACE2 receptor to infect cells and could "replicate efficiently in primary human airway cells," they wrote. (Both SARS and SARS-CoV-2 use the ACE2 receptor as the entry point into cells.)

Zhengli and her colleagues stressed the importance of monitoring and studying the SARS coronaviruses to help prevent another pandemic.

"Thus, we propose that monitoring of SARS-CoV evolution at this and other sites should continue, as well as examination of human behavioral risk for infection and serological surveys of people, to determine if spillover is already occurring at these sites and to design intervention strategies to avoid future disease emergence," they wrote.

Related: 20 of the worst epidemics and pandemics in history

The WIV lab, along with researchers in the U.S. and Switzerland, showed in 2015 the scary-good capability of bat coronaviruses to thrive in human cells. In that paper, which was published in 2015 in the journal Nature Medicine, they described how they had created a chimeric SARS-like virus out of the surface spike protein of a coronavirus found in horseshoe bats, called SHC014, and the backbone of a SARS virus that could be grown in mice. The idea was to look at the potential of coronaviruses circulating in bat populations to infect humans. In a lab dish, the chimeric coronavirus could infect and replicate in primary human airway cells; the virus also was able to infect lung cells in mice.

That study was met with some pushback from researchers who considered the risk of that kind of research to outweigh the benefits. Simon Wain-Hobson, a virologist at the Pasteur Institute in Paris, was one of those scientists. Wain-Hobson emphasized the fact that this chimeric virus "grows remarkably well" in human cells, adding that "If the virus escaped, nobody could predict the trajectory," Nature News reported.

None of this can show the provenance of SARS-CoV-2.

But scientists can start to rule out an idea that the pandemic-causing coronavirus was engineered in that lab or further created as a bioweapon. Researchers say the overwhelming evidence indicates this is a natural-borne virus that emerged from an animal host, likely a bat, and was not engineered by humans.

Related: 28 devastating infectious diseases

"This origin story is not currently supported at all by the available data," said Adam Lauring, an associate professor of microbiology, immunology and infectious diseases at the University of Michigan Medical School. Lauring pointed to a study published March 17 in the journal Nature Medicine, which provided evidence against the idea that the virus was engineered in a lab.

In that Nature medicine study one of the strongest rebukes of this idea Kristian Andersen, an associate professor of immunology and microbiology at Scripps Research, and his colleagues analyzed the genome sequences of SARS-CoV-2 and coronaviruses in animals. They found that a key part of SARS-CoV-2, the spike protein that the virus uses to attach to ACE2 receptors on the outsides of human cells, would almost certainly have emerged in nature and not as a lab creation.

"This analysis of coronavirus genome sequences from patients and from various animals suggests that the virus likely arose in an animal host and then may have undergone further changes once it transmitted and circulated in people," Lauring told Live Science.

That may rule out deliberate genetic engineering, but what about other scenarios that point to bats as the natural hosts, but WIV as the source of the outbreak?

Although researchers will likely continue to sample and sequence coronaviruses in bats to determine the origin of SARS-CoV-2, "you can't answer this question through genomics alone," said Dr. Alex Greninger, an assistant professor in the Department of Laboratory Medicine and an assistant director of the Clinical Virology Laboratory at the University of Washington Medical Center. That's because it's impossible to definitively tell whether SARS-CoV-2 emerged from a lab or from nature based on genetics alone. For this reason, it's really important to know which coronaviruses were being studied at WIV. "It really comes down to what was in the lab," Greninger told Live Science.

However, Lauring said that based on the Nature Medicine paper, "the SARS-CoV-2 virus has some key differences in specific genes relative to previously identified coronaviruses the ones a laboratory would be working with. This constellation of changes makes it unlikely that it is the result of a laboratory 'escape,'" he said.

As for what viruses were being studied at WIV, Zhengli says she did a thorough investigation. When she first was alerted to the viral outbreak in Wuhan on the night of Dec. 30, 2019, Zhengli immediately put her lab to work sequencing the genomes of SARS-CoV-2 from infected patients and comparing the results with records of coronavirus experiments in her lab. She also looked for any mishandling of viral material used in any experiments, Scientific American reported. She didn't find any match between the viruses her team was working with from bat caves and those found in infected patients. "That really took a load off my mind," she told Scientific American. "I had not slept a wink for days."

At the beginning of February, Zhengli sent a note over WeChat to reassure her friends that there was no link, saying "I swear with my life, [the virus] has nothing to do with the lab," the South China Morning Post reported Feb. 6. Zhengli and another colleague, Peng Zhou, did not reply to a Live Science email requesting comment.

The Wuhan lab does work with the closest known relative of SARS-CoV-2, which is a bat coronavirus called RaTG13, evolutionary virologist Edward Holmes, of the Charles Perkins Center and the Marie Bashir Institute for Infectious Diseases and Biosecurity at the University of Sydney, said in a statement from the Australian Media Center. But, he added, "the level of genome sequence divergence between SARS-CoV-2 and RaTG13 is equivalent to an average of 50 years (and at least 20 years) of evolutionary change." (That means that in the wild, it would take about 50 years for these viruses to evolve to be as different as they are.)

Though no scientists have come forth with even a speck of evidence that humans knowingly manipulated a virus using some sort of genetic engineering, a researcher at Flinders University in South Australia lays out another scenario that involves human intervention. Bat coronaviruses can be cultured in lab dishes with cells that have the human ACE2 receptor; over time, the virus will gain adaptations that let it efficiently bind to those receptors. Along the way, that virus would pick up random genetic mutations that pop up but don't do anything noticeable, said Nikolai Petrovsky, in the College of Medicine and Public Health at Flinders.

"The result of these experiments is a virus that is highly virulent in humans but is sufficiently different that it no longer resembles the original bat virus," Petrovsky said in a statement from the Australian Media Center. "Because the mutations are acquired randomly by selection, there is no signature of a human gene jockey, but this is clearly a virus still created by human intervention."

If that virus infected a staff member and that person then traveled to the nearby seafood market, the virus could have spread from there, he said. Or, he added, an "inappropriate disposal of waste from the facility" could have infected humans directly or from a susceptible intermediary, such as a stray cat.

Though we may never get a definitive answer, at least in the near-term, some say it doesn't matter.

"No matter the origin, evolution in nature and spillover to humans, accidental release from a lab, or deliberate release or genetic manipulation of a pathogen in the lab the way you develop countermeasures is the same," Keusch told Live Science. "Since one can never say 100% for anything, I think we always need to be aware of all possibilities in order to contravene. But the response to develop what is needed to respond, control and eliminate the outbreak remains the same."

Live Science senior writer Rachael Rettner contributed to this report.

Originally published on Live Science.

View original post here:
Wuhan lab says there's no way coronavirus originated there. Here's the science. - Livescience.com

Weekly Update: Global Coronavirus Impact and Implications on Immunology Drug Market Value Projected to Expand by 2019-2026 – Jewish Life News

Assessment of the Global Immunology Drug Market

Persistence Market Research recently published a market report which offers valuable insights pertaining to the various factors that are likely to influence the prospects of the Immunology Drug market through the forecast period (2019-2029). The study takes into account the historical and current market trends to predict the course of the Immunology Drug market in the upcoming years. Further, the growth opportunities, drivers, and major challenges faced by market players and the impact of the COVID-19 pandemic on the Immunology Drug market are discussed in detail.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/15259

Regional Outlook

The team of analysts at PMR, track the major innovations and developments within the Immunology Drug market sphere in various geographies. The market share, size, and value of each region are discussed in the report along with explanatory graphs, tables, and figures.

Competitive Outlook

This chapter of the report discusses the ongoing developments of leading companies operating in the Immunology Drug market. The major changes that are likely to occur in the business models of several companies post the COVID-19 pandemic is also highlighted in detail. The product portfolio, pricing strategy, the regional and global presence of each company is thoroughly discussed in the report.

Product Adoption Analysis

The report offers valuable insights related to the adoption pattern, supply-demand ratio, and pricing structure of each product.

key players and products offered

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/15259

Critical Market Information Enclosed in the Report:

Doubts Related to the Immunology Drug Market Catered to in the Report:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/15259

Why Opt for Persistence Market Research?

More:
Weekly Update: Global Coronavirus Impact and Implications on Immunology Drug Market Value Projected to Expand by 2019-2026 - Jewish Life News

Temperatures and pollen counts both predicted to rise this week in Seattle area – Seattle Times

Its on, allergy sufferers. Especially if youre sensitive to tree pollen.

Pollen counts are predicted to soar for the rest of this week as temperatures through most of the Puget Sound region climb toward 70 degrees on Thursday and Friday.

Pollen count is predicted to be very high Thursday through Sunday, according to theNorthwest Asthma & Allergy Center.

Seattle-area allergy experts say that once your allergies are activated and apparently Western Washington is one of the best places to discover whether youre allergic to tree pollen you take a deep breath on a beautiful spring day, and instantly your mast cells jump into action.

The key feature of allergies and our immune system in general is also the reason they are persistent and frustrating, said Dr. Jakob von Moltke, an assistant professor of immunology at the UW School of Medicine. You can go a whole winter without any issues, and then your immune system is triggered in seconds.

And allergists say the masks many people are wearing lately havent really mitigated pollen allergy symptoms: sneezing, runny noses, postnasal drip, and itchy, puffy, watery eyes. (That said, you should wear one when youre out in public, to protect yourself and others from the novel coronavirus especially if youre sneezing, which launches your germs into the air.)

If there is a difference (for allergy sufferers during the pandemic), it may be because people are not walking around outside a lot and are staying indoors, which is what we recommend, said Dr. Lahari Rampur, a UW Medicine allergy and immunology professor.

It can help to keep your windows closed, saidDr. Scott Itano, medical center chief at Kaiser Permanente Northgate Medical Center.

Most plants release their pollen in the middle of the night, so leaving windows open at night as many people do when the weather gets warm is one of the worst things you can do, he said. Then, you will be allergic inside and outside your house.

And if you are taking medicine to combat allergies, such as allergy pills and nasal steroid sprays, Itano recommends taking it at night before bed to help suppress the allergic reaction before it happens.

Read the rest here:
Temperatures and pollen counts both predicted to rise this week in Seattle area - Seattle Times

LJI Scientists Awarded New Funding to Combat COVID-19 – Times of San Diego

Share This Article:To aid vaccine design, researchers at LJI will investigate how a diverse population fights off viral attack

The coronavirus behind COVID-19 is new in the human population, meaning few have any natural immunity to the disease. Yet many people are able to fight off the disease through an effective immune system response. Scientists at theLa Jolla Institute for Immunology(LJI) are working to figure out how to help everyone combat the virus.

Support Times of San Diego's growthwith a small monthly contribution

The laboratory of LJI professorAlessandro Sette, Dr. Biol. Sci., has been awarded $500,000 from the National Institutes of HealthsNational Institute of Allergy and Infectious Diseasesto study how the human immune system recognizes the novel coronavirus. The research team will hunt for sites on the coronavirus surface that trigger an immune system responsesites which may be important to target through a COVID-19 vaccine.

This will further allow us to tackle key issues for research right now, Sette said. The funding will allow us to measure immune responses and ask questions related to how immune responses translate in more or less severe disease, which response we want, which response we want to avoidand what response should a vaccine induce? We are also eager to make all data available to the scientific community, basic researchers, industry, and vaccine developers as fast as we possibly can.

At the end of this, we want a map of the virus that tells us what parts of the virus are recognized by the immune system, and that will guide vaccine design, said LJI research assistant professor Daniela Weiskopf, a member of the Sette lab.

The new project will take advantage of LJIs expertise in identifying epitopes, small molecular structures on the surface of a pathogen. When immune cells spot foreign epitopes, they step up to defend the body. This means that scientists designing vaccines need to know which epitopes the immune system can see. Past studies in the Sette lab have shed light on vulnerable epitopes on pathogens responsible for diseases such as dengue fever, malaria and tuberculosis.

We already have everything in house: methods, technical set-ups and expertise. We just have to look at a different virus now, Weiskopf said.

The labwill investigate epitopes targeted by a diverse group of COVID-19 survivors. They will also analyze samples from uninfected donors. These donors may harbor immune memory against other types of coronavirus that only cause the common cold, and researchers are curious whether these immune cells may also recognize epitopes of the novel coronavirus (SARS-CoV-2).

The researchers will add their findings to theImmune Epitope Database(IEDB), a free online resource run by Sette and LJI professorBjoern Peters, Ph.D.Through the IEDB, researchers worldwide can access this coronavirus epitope data and even add their own.

Learn more about COVID-19 research underway at LJI:https://www.lji.org/covid-19/research-efforts-underway/

The new supplement is part of NIH contract #75N93019C00065.

LJI Scientists Awarded New Funding to Combat COVID-19 was last modified: April 17th, 2020 by Debbie L. Sklar

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Read this article:
LJI Scientists Awarded New Funding to Combat COVID-19 - Times of San Diego

Zania Stamataki – The Conversation UK

Profile Articles Activity

Dr Stamataki is interested in applying immunology and cell biology methodologies to understand liver diseases from autoimmune, viral or metabolic injury. Her team is using authentic human liver tissues to develop new therapies that restore immune regulation in liver inflammation and cancer.

Her team is fascinated by the intricate architecture of the liver and they are investigating how cells of the immune system influence and are influenced by the liver microenvironment to coordinate immune regulation.

They use cell biology, immunology and virology experiments to understand and quantify interactions between immune cells and liver resident cells. They build models to manipulate these interactions using human tissues and they develop novel drug candidate molecules, in collaboration with industrial partners.

Read more here:
Zania Stamataki - The Conversation UK

Birmingham experts join forces to improve COVID-19 antibody diagnosis – University of Birmingham

Coronavirus

Birmingham experts are working together on improving detection of SARS-CoV-2 antibodies the best way of fighting the disease as the search for a vaccine continues.

Working with the Binding Site, and through Birmingham Health Partners alongside colleagues at University Hospitals Birmingham NHS Foundation Trust experts at the University of Birminghams Clinical Immunology Service aim to improve antibody diagnosis.

This will help to identify patients where prompt medical intervention can prevent them having to go into intensive care, whilst guiding relaxation of the COVID-19 lockdown by identifying the proportion of communities at large that are now immune.

David Adams, Head of the College of Medical and Dental Sciences and Director of Birmingham Health Partners, commented: The current COVID-19 pandemic represents a previously unimaginable global challenge. Without vaccination, the role of antibody testing, as a means to assess community infection, is of paramount importance.

By bringing together unrivalled academic, clinical and commercial expertise in antibody testing this collaboration has the potential to deliver a reliable test to detect antibodies against coronavirus. If successful, this will be a game changer in our fight against Covid-19.

He added that commercial and academic collaborative partnerships would be required to rapidly develop, verify and validate such tests.

With over 40 years experience in developing novel in vitro diagnostics (IVD) based on the generation of highly-specific monoclonal and polyclonal immunoglobulins, the Clinical Immunology Service is well-placed to coordinate such an effort.

The Binding Site leads the way in specialist protein diagnostics. Built on strong scientific foundations with extensive expertise in antibody specificity technology, Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of patients across a range of cancers and immune system disorders.

Charles de Rohan, CEO, The Binding Site, commented: Binding Site came out of the University of Birmingham in the 1980s and now produces more than 30 million IVD tests for worldwide sale every year.

Weve maintained our close collaboration with the University of Birmingham and researchers such as Professor Mark Drayson, Dr. Alex Richter and Dr. Aarnoud Huissoon. We share their scientific passion and are delighted to continue our partnership with them during this unprecedented time.

University Hospitals Birmingham NHS Foundation Trust (UHB) is one of the largest teaching hospital trusts in England, serving a regional, national and international population.

Professor Simon Ball, Chief Medical Officer, University Hospitals Birmingham NHS Foundation Trust, commented: We are proud of our long-standing association with the Binding Site. I have no doubt that this collaboration will provide significant assistance to our efforts to deliver the best care possible to patients affected by Covid-19.

Excerpt from:
Birmingham experts join forces to improve COVID-19 antibody diagnosis - University of Birmingham

Coronavirus immunity permits for Washingtonians? ‘We’re not quite there yet’ – KUOW News and Information

As the Covid-19 death toll rises, scientists are racing to understand the human body's response to the disease.

While some coronavirus antibody tests have been approved for use in the U.S., several key questions remain: What happens to the immune system after a person recovers from the virus? Could they be reinfected, and are they still a risk to others?

The Trump administration and some European countries have proposed allowing nonessential employees to return to work if they can prove they're no longer capable of spreading the virus.

This would be done by testing for coronavirus antibodies, the proteins created by the immune system in response to the presence of a virus. U.S. officials said last week that coronavirus antibody tests would soon hit the national market.

As of April 15, the U.S. Food and Drug Administration has authorized three coronavirus antibody tests. But some scientists argue that not enough is presently known about how novel coronavirus antibodies work, in order to correctly determine whether someone is immune.

"It's very likely that there are a large number of people out there that have been infected have been asymptomatic and did not know they were infected," said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases during an April 10 appearance on CNN's New Day. Fauci is also a member of the federal coronavirus task force.

"If their antibody test is positive, one can formulate kind of strategies about whether or not they would be at risk or vulnerable to getting reinfected, this will be important for healthcare workers for first line fighters those kinds of people," he said. But those tests need to be validated, he added.

Fauci also stated that the prospect of people receiving immunity permits "is something that's being discussed" and that such a policy "might actually have some merit under certain circumstances."

But before the feasibility of such a policy can be weighed, the research must first catch up, said Dr. Helen Chu with the University of Washington's epidemiology department.

"We do think that having immunity to the virus may be protective," Chu told KUOW's The Record. "We don't know what an antibody test, at this point, means though. People who are currently infected and then recover from the virus we don't actually know what the immune signature of recovery is."

Chu said it's not clear which particular antibodies could protect a person against Covid-19.

Researchers also have yet to discover how high those antibody levels would need to be to provide immunity, or how long they would last, she said. Moreover, having antibodies for the novel coronavirus wouldn't necessarily mean a person isn't still infectious to others.

"The idea of being able to have a test to say that you're protected and you can go back and work we're not quite there yet," she said.

While there's still a great deal of uncertainty surrounding the immune system's response to Covid-19, Chu said seasonal flu epidemics could offer a window of insight.

"Once you get infected [with influenza] and you develop a protective response, that doesn't last for very long," she said. "And by the next year, you're going to be reinfected again or you're going to get another vaccine and that'll protect you for a certain amount of time but then you become susceptible again. And we don't know how coronavirus behaves."

The University of Washington's Clinical Immunology Laboratory has set out to help answer some of the looming questions about coronavirus antibodies.

"Basically, we're looking for antibodies that bind to the coronavirus proteins," said Dr. Susan Fink, assistant director of the University of Washington's Clinical Immunology Laboratory.

Thus far, the tests conducted by Fink's team have yielded varying outcomes.

"We've looked at a number of different assays, basically to look for performance characteristics are they sensitive, are they specific? And one of the things that we found is that [with] the different sort of ways that you can measure antibodies, we get very different results," she said.

Samples collected prior to the pandemic have provided some insight, albeit inconclusive, Fink said. Her team is still trying to figure out the best method for measuring coronavirus antibodies.

"We see reactivity and the way we're interpreting that is we think that those are probably false positives," Fink said, adding that her team attributes this to the presence of antibodies for other coronavirus strains not the one at the center of our current pandemic.

The Clinical Immunology Laboratory is also probing the potential for herd immunity against Covid-19: The concept of vaccinating a high percentage of people in a community to prevent them from contracting or transmitting an infectious disease, thus suppressing it.

"If we can develop an assay that we know is pretty specific for the novel coronavirus, as opposed to other coronaviruses that people have been infected with, then we can start to ask the questions about, 'Well how many people have actually developed these antibodies?'"

However, Fink said a lot more research is needed before drawing any conclusions about who might be immune to the virus.

The University of Washington's Virology Lab on Friday announced that it will begin performing widespread antibody tests starting early next week. The tests are manufactured by the Illinois-based health care company Abbott Laboratories, Inc. and people will be able to get them through their health care provider.

Read more about the new antibody tests here.

Bill Radke contributed to this report. Additionally, this report was updated on Friday, April 17 to include new information about antibody tests that will be available to Washingtonians in the coming week.

Read this article:
Coronavirus immunity permits for Washingtonians? 'We're not quite there yet' - KUOW News and Information

Yuan He wins Provost’s University Research Grant for inflammation project – The South End

The research of Yuan He, Ph.D., is getting a boost from the Wayne State University Office of the Provost in the form of a 2020-2021 University Research Grant from Associate Provost for Faculty Development and Faculty Success Annmarie Cano.

I feel very happy to be selected for this grant, which will provide the essential resource for pursuing my research projects, he said.

Dr. He, an assistant professor of Biochemistry, Microbiology and Immunology in the School of Medicine, will use the grant to support his project, Molecular Mechanism of NEK7-mediated NLRP3 inflammasome activation.

Excessive inflammation is associated with many human diseases. Inflammation is initiated by sensor proteins of our innate immune cells that detect microbial infection and tissue injury. NLRP3 belongs to one type of sensor proteins that are activated to form intracellular multiple protein complexes called inflammasomes, and its aberrant activation is implicated in several human diseases, such as arthritis, Alzheimers disease, diabetes and atherosclerosis, he said.

NEK7 has emerged as a critical regulator of NLRP3 inflammasome activation. However, how NEK7 mediates NLRP3 inflammasome activation remains unclear.

Our studies aim to decipher the underlying molecular mechanism of NEK7-mediated NLRP3 inflammasome activation and might facilitate the development of novel treatment strategies for NLRP3-driven diseases, Dr. He said.

Read the original post:
Yuan He wins Provost's University Research Grant for inflammation project - The South End

Eating varied diet will help body fight Covid-19, says scientist – expressandstar.com

Eating a diverse and varied diet provides the best chance of boosting the immune system to fight Covid-19, according to a scientist.

Philip Calder, a professor of nutritional immunology at the University of Southampton, has produced a report advising the public to ensure they eat a mixed diet to help combat the virus.

His research also shows that supplements are a safe, effective and low cost way to support an optimal immune system.

A university spokesman said: A diet with a diverse and varied mixture of vegetables, fruits, nuts, seeds and pulses, along with some meat, fish and dairy products provides the vitamins, minerals and other nutrients the immune system needs for optimal function.

Prof Calder said: The strength of somebodys immune systems will not influence whether they get coronavirus; handwashing and social distancing are the best ways to avoid that.

However, the immune system helps the body deal with the virus if they are infected and what we want is a system that functions properly when its challenged with bacteria and viruses.

The university spokesman added: Among the foods Professor Calder recommends are a variety of fruits and vegetables which are a good source of vitamins and minerals that are important for supporting the immune system.

Foods that are high in fibre are also important as some of the undigested fibre in the gut can promote the growth of good bacteria which interact with the immune system to make it work better.

The third recommendation is oily fish which is a source of omega 3 fatty acids that help to regulate and control the immune system.

Finally, meat is important as a good source of nutrients such as iron and vitamin B12, so people who do not eat meat should consider supplements.

Whilst consuming commercial probiotic products can have a role to play by seeding good bacteria in the gut Professor Calder recommends plant-based food and fibre as an alternative as these provide an environment to grow the good bacteria that are already in the large intestine.

Professor Calder added: The present situation with Covid-19 shows that we cannot just rely on vaccinations to limit the impact of respiratory infections.

Improving our nutrition is a very straightforward step that we can all take to help our bodies deal with infections and limit the emergence of new, more virulent strains of viruses.

We therefore strongly encourage public health officials to make sure nutritional strategies are included in all their messaging about coping with viral infections.

Link:
Eating varied diet will help body fight Covid-19, says scientist - expressandstar.com

Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer – BioSpace

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of D. Mark McClung as Executive Vice President and Chief Business Officer. Mr. McClung will oversee commercial strategic planning, alliance management and corporate and business development.

Mr. McClungs appointment is the latest in the evolution of Sangamos leadership implemented over the last three years as the Companys technology and research programs have advanced into a diversified pipeline of therapeutic product candidates in various stages of clinical development. During this period, Sangamo has also appointed executive vice presidents overseeing R&D, manufacturing, legal and finance.

Im excited to welcome Mark to Sangamo. With our first product candidate entering Phase 3 and our broad pipeline of proprietary and partnered programs advancing in development, we are increasingly focused on late stage development and commercialization strategies for genomic medicines. Mark has extensive experience leading commercial organizations in therapeutic areas where innovative products have disrupted standards of care, said Sandy Macrae, Sangamos CEO.

From 2015 through 2019, Mr. McClung was Vice President and General Manager of Global Oncology Commercial at Amgen, which he joined from Onyx Pharmaceuticals where he had served as Chief Commercial Officer. For two decades prior, Mr. McClung held roles of increasing responsibility at GlaxoSmithKline in marketing and sales, commercial operations, and general management in the United States and Europe, including as Vice President and Head of Global Commercial for GSK Oncology from 2009 2013.

Over the next decade, genomic medicines have the potential to transform the practice of health care across therapeutic areas from rare monogenic diseases to immunology and oncology, and even to highly prevalent neurological disorders such as Alzheimers disease and Parkinsons disease, Mr. McClung commented. With its deep scientific expertise, diverse technology platforms, broad pipeline and significant collaborations, Sangamo is well positioned for this new era, and Im thrilled to join the Company at this time.

Stephane Boissel, Executive Vice President of Corporate Strategy, will leave Sangamo at the end of July and eventually return to an entrepreneurial project. Mr. Boissel joined Sangamo in 2018 following the acquisition of TxCell (now Sangamo France), where he had served as CEO.

Stephanes impactful contributions to Sangamo will endure for many years. He has driven several remarkable deals to fruition, including most recently our transaction with Biogen, which is among the largest preclinical collaboration deals ever, Macrae said. It has been an enormous pleasure working with Stephane these last two years, and we wish him every success in the future.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit http://www.sangamo.com.

Sangamo Forward Looking Statements

This press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize immunology and oncology therapies, therapies to treat rare monogenic diseases, neurological diseases and other diseases and other therapies and the timing and availability of such therapies, the potential for Sangamo to receive upfront licensing fees and earn milestone payments and royalties under the Biogen and other collaborations and the timing of such fees, payments and royalties, Sangamos product pipeline, technology platforms and scientific expertise, Sangamos financial resources and expectations and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to: the research and development process; the regulatory approval process for product candidates; the commercialization of approved products; the potential for technological developments that obviate Sangamo's technologies; the potential for Biogen to breach or terminate the collaboration agreement; and the potential for Sangamo to fail to realize its expected benefits of the Biogen and other collaborations. There can be no assurance that Sangamo will earn any upfront licensing fees or milestone or royalty payments under the Biogen or other collaborations or obtain regulatory approvals for product candidates arising from these collaborations. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200417005086/en/

The rest is here:
Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer - BioSpace